

# Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222

---

Status	RECRUITING
Phase	Phase 2
Sponsor	NS Pharma, Inc.
Enrollment	45 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Ability to provide written informed consent prior to participation in the study.
- Male or female subjects aged ≥18 years at the time the informed consent form is signed.
- Diagnosis of EGPA: Subjects who have been diagnosed with EGPA based on the history or presence of eosinophilia plus at least a history or presence of 2 of additional features of EGPA.
- Subjects receive background OGC dose of ≥7.5 mg/day with or without stable treatment with Mepolizumab/Benralizumab.
- Use of adequate contraception.

### Exclusion (19)

- Current diagnosis of either granulomatosis with polyangiitis or microscopic polyangiitis
- Imminently life-threatening EGPA at the time of screening.
- History or presence of any form of cancer within 5 years prior to screening.
- Serious liver, renal, blood, or psychiatric disease
- Severe or clinically significant cardiovascular disease uncontrolled with standard treatment

... and 14 more (see full listing online)

## Locations (34 total)

---

National Jewish Health, Denver, Colorado, United States  
Mayo Clinic, Rochester, Minnesota, United States  
Cleveland Clinic, Cleveland, Ohio, United States  
... and 31 more locations